newsfilter
← Latest News
GlobeNewswire·

Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

STLNTOIIW
  • Starling Oncology reported third quarter 2026 results with consolidated revenue of $169.8 million, up 24.3% year over year.
  • Specialty pharmacy revenue reached $109 million, a 44% increase year over year, with a 24% gross margin.
  • Capitated revenue grew 40% year over year, while the medical loss ratio improved to 81.0% from 85.5% in the prior quarter.
  • The company reported a net loss of $15.7 million, compared to a net loss of $16.5 million in the same period last year.
  • Adjusted EBITDA turned positive at $3.4 million, marking the second consecutive quarter of positive performance.
  • Starling Nexus, a proprietary utilization management portal, is now live for network providers to submit prior authorizations.
  • Cash and cash equivalents stood at $36.9 million as of September 30, 2026.
  • The company affirmed its full-year 2026 revenue guidance of $650 million to $670 million.
  • Updated full-year 2026 Adjusted EBITDA guidance was set at $2 million to $7 million, revised down from $4 million to $6 million.
  • Fourth quarter 2026 Adjusted EBITDA outlook is projected between $3 million to $5 million as the company ramps Florida delegated lives.
  • Management anticipates approximately $110 million in capitated revenue for 2026.
  • The Medical Loss Ratio is expected to range between 85% to 90% in 2027 following the onboarding of new lives.
  • Starling Oncology operates over 400 clinicians across 322 clinics in 17 markets with 2.2 million patients under value-based contracts.
  • A conference call to discuss results will be held on November 5, 2026, at 5:00 p.m. Eastern Time.
Company
Starling Oncology
Keywords
Nasdaq:STLN, Starling Oncology